This afternoon's spike in shares of Complete Genomics (GNOM +7.1%) may be attributable to remarks by CEO Cliff Reid on a recent paper that finds GNOM's whole genome sequencing service more accurate than Illumina's (ILMN +0.7%) HiSeq 2000 instrument. Reid says GNOM's sequencing produces 1/50th as many errors as ILMN's.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs